<p>Acumen Pharmaceuticals, Inc.（納斯達克代碼：ABOS - 獲取免費報告）內部人士 James Doherty 於 1 月 8 日（星期四）出售了 6,467 股公司的股票。該股票以平均價格 1.82 美元出售，總交易額為 11,769.94 美元。交易完成後，該內部人士持有 54,033 股公司的股票，估值約為 98,340.06 美元。這筆交易代表其持股減少了 10.69%。該交易已在與 SEC 的法律文件中披露，具體內容可通過此鏈接獲取。</p>
<p>獲取 <strong>Acumen Pharmaceuticals</strong> 的提醒：</p>
<h2>Acumen Pharmaceuticals 股票表現</h2>
<ul>
<li>MarketBeat 週報 – 7/17 - 7/21</li>
</ul>
<p>在週五的午盤交易中，ABOS 的股價下跌 0.05 美元，達到 1.81 美元。該公司的股票交易量為 284,595 股，而其平均交易量為 263,872 股。該公司的 50 日移動平均價格為 1.95 美元，200 日移動平均價格為 1.68 美元。該股票的市值為 1.0963 億美元，市盈率為-0.82，貝塔值為 0.23。該公司的債務與股本比率為 0.29，速動比率為 6.02，流動比率為 6.02。Acumen Pharmaceuticals, Inc.的 12 個月最低價為 0.86 美元，最高價為 2.46 美元。</p>
<p>Acumen Pharmaceuticals（納斯達克代碼：ABOS - 獲取免費報告）最近於 11 月 12 日（星期三）發佈了季度財報。該公司報告每股收益（EPS）為-0.44 美元，超出市場共識預期的-0.63 美元，差額為 0.19 美元。股票分析師預測，Acumen Pharmaceuticals, Inc.在當前年度的每股收益將為-1.56 美元。</p>
<h2>分析師評級變動</h2>
<ul>
<li>Acumen 因阿爾茨海默病研究而飆升……華爾街預計其股價將翻倍</li>
</ul>
<p>ABOS 近期成為多份分析師報告的主題。華爾街 Zen 在 12 月 21 日（星期日）的一份研究報告中將 Acumen Pharmaceuticals 的股票評級從 “賣出” 上調至 “持有”。美國銀行在 11 月 18 日（星期二）的一份研究報告中將 Acumen Pharmaceuticals 的目標價格從 9.00 美元下調至 8.00 美元，並對該股票給予 “買入” 評級。最後，Weiss Ratings 在 10 月 14 日（星期二）的一份研究報告中重申了對 Acumen Pharmaceuticals 的 “賣出（d-）” 評級。四位股票研究分析師對該股票給予了 “買入” 評級，一位分析師給予了 “賣出” 評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “適度買入”，共識目標價格為 6.75 美元。</p>
<p><strong>查看我們對 ABOS 的最新分析</strong></p>
<h2>對 Acumen Pharmaceuticals 的對沖基金看法</h2>
<p>幾家大型投資者最近對該公司的持股進行了調整。AQR Capital Management LLC 在第一季度購買了 Acumen Pharmaceuticals 的新股份，價值約為 46,000 美元。Y Intercept Hong Kong Ltd 在第二季度收購了 Acumen Pharmaceuticals 的新股份，價值約為 291,000 美元。Marshall Wace LLP 在第二季度購買了 Acumen Pharmaceuticals 的新股份，價值為 160,000 美元。Qube Research &amp; Technologies Ltd 在第二季度將其在 Acumen Pharmaceuticals 的持股增加了 160.0%。Qube Research &amp; Technologies Ltd 現在擁有 57,559 股該公司的股票，價值 67,000 美元，此前在上個季度又購買了 35,424 股。最後，Jane Street Group LLC 在第二季度將其在 Acumen Pharmaceuticals 的持股增加了 1,526.0%。Jane Street Group LLC 現在擁有 175,670 股該公司的股票，價值 204,000 美元，此前在上個季度又收購了 164,866 股。機構投資者持有該公司 71.01% 的股票。</p>
<h2>關於 Acumen Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>Acumen Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，專注於發現和開發用於神經退行性疾病的口服小分子療法。該公司利用一種集成了化學蛋白質組學、高通量篩選和計算化學的專有藥物發現平台，旨在識別和優化選擇性調節病理性蛋白質聚集的化合物。其方法旨在解決阿爾茨海默病、帕金森病、肌萎縮側索硬化症及相關蛋白病等疾病的基礎生物學問題。</p>
<p>該公司的產品管線包括多個處於不同臨牀前和早期臨牀開發階段的主要候選藥物。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Acumen Pharmaceuticals</li>
<li>Elon 將 SpaceX 上市！100 美元的首次公開募股機會！</li>
<li>請勿刪除，立即閲讀</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
<li>今年你花的最值得的 19 美元。</li>
<li>自 2007 年以來首次：所有警告均已激活</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJPUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJPUw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Acumen Pharmaceuticals 嗎？</h2>
<p>在你考慮 Acumen Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前立即購買……而 Acumen Pharmaceuticals 並不在名單上。</p>
<p>雖然 Acumen Pharmaceuticals 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ABOS

<p>Acumen Pharmaceuticals（納斯達克代碼：ABOS）的內部人士 James Doherty 於 1 月 8 日以每股 1.82 美元的價格出售了 6,467 股公司股票，總計 11,769.94 美元。此次交易後，他持有 54,033 股，反映出其持股減少了 10.69%。該出售在 SEC 文件中披露。Acumen 的股票交易價格下跌至 1.81 美元，市值為 1.0963 億美元，市盈率為-0.82。分析師對該股票的評級不一，普遍評級為 “適度買入”，目標價格為 6.75 美元</p>

<p>Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) insider James Doherty sold 6,467 shares of the company's stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $1.82, for a total transaction of $11,769.94. Following the completion of the transaction, the insider owned 54,033 shares of the company's stock, valued at approximately $98,340.06. This trade represents a 10.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link.</p>
<div class="lb-trans"><p>Acumen Pharmaceuticals, Inc.（納斯達克代碼：ABOS - 獲取免費報告）內部人士 James Doherty 於 1 月 8 日（星期四）出售了 6,467 股公司的股票。該股票以平均價格 1.82 美元出售，總交易額為 11,769.94 美元。交易完成後，該內部人士持有 54,033 股公司的股票，估值約為 98,340.06 美元。這筆交易代表其持股減少了 10.69%。該交易已在與 SEC 的法律文件中披露，具體內容可通過此鏈接獲取。</p>
</div><p>Get <strong>Acumen Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Acumen Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Acumen Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Acumen Pharmaceuticals 股票表現</h2>
</div><ul>
<li>MarketBeat Week in Review – 7/17 - 7/21</li>
</ul>
<div class="lb-trans"><ul>
<li>MarketBeat 週報 – 7/17 - 7/21</li>
</ul>
</div><p>Shares of ABOS traded down $0.05 during mid-day trading on Friday, reaching $1.81. 284,595 shares of the company's stock traded hands, compared to its average volume of 263,872. The business's 50-day moving average price is $1.95 and its 200-day moving average price is $1.68. The stock has a market capitalization of $109.63 million, a P/E ratio of -0.82 and a beta of 0.23. The company has a debt-to-equity ratio of 0.29, a quick ratio of 6.02 and a current ratio of 6.02. Acumen Pharmaceuticals, Inc. has a 12 month low of $0.86 and a 12 month high of $2.46.</p>
<div class="lb-trans"><p>在週五的午盤交易中，ABOS 的股價下跌 0.05 美元，達到 1.81 美元。該公司的股票交易量為 284,595 股，而其平均交易量為 263,872 股。該公司的 50 日移動平均價格為 1.95 美元，200 日移動平均價格為 1.68 美元。該股票的市值為 1.0963 億美元，市盈率為-0.82，貝塔值為 0.23。該公司的債務與股本比率為 0.29，速動比率為 6.02，流動比率為 6.02。Acumen Pharmaceuticals, Inc.的 12 個月最低價為 0.86 美元，最高價為 2.46 美元。</p>
</div><p>Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.19. Equities analysts predict that Acumen Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.</p>
<div class="lb-trans"><p>Acumen Pharmaceuticals（納斯達克代碼：ABOS - 獲取免費報告）最近於 11 月 12 日（星期三）發佈了季度財報。該公司報告每股收益（EPS）為-0.44 美元，超出市場共識預期的-0.63 美元，差額為 0.19 美元。股票分析師預測，Acumen Pharmaceuticals, Inc.在當前年度的每股收益將為-1.56 美元。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><ul>
<li>Acumen Soars on Alzheimer's Study...Street Sees It Doubling</li>
</ul>
<div class="lb-trans"><ul>
<li>Acumen 因阿爾茨海默病研究而飆升……華爾街預計其股價將翻倍</li>
</ul>
</div><p>ABOS has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of Acumen Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Sunday, December 21st. Bank of America lowered their target price on shares of Acumen Pharmaceuticals from $9.00 to $8.00 and set a &#34;buy&#34; rating on the stock in a research note on Tuesday, November 18th. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Acumen Pharmaceuticals in a research note on Tuesday, October 14th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $6.75.</p>
<div class="lb-trans"><p>ABOS 近期成為多份分析師報告的主題。華爾街 Zen 在 12 月 21 日（星期日）的一份研究報告中將 Acumen Pharmaceuticals 的股票評級從 “賣出” 上調至 “持有”。美國銀行在 11 月 18 日（星期二）的一份研究報告中將 Acumen Pharmaceuticals 的目標價格從 9.00 美元下調至 8.00 美元，並對該股票給予 “買入” 評級。最後，Weiss Ratings 在 10 月 14 日（星期二）的一份研究報告中重申了對 Acumen Pharmaceuticals 的 “賣出（d-）” 評級。四位股票研究分析師對該股票給予了 “買入” 評級，一位分析師給予了 “賣出” 評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “適度買入”，共識目標價格為 6.75 美元。</p>
</div><p><strong>Check Out Our Latest Analysis on ABOS</strong></p>
<div class="lb-trans"><p><strong>查看我們對 ABOS 的最新分析</strong></p>
</div><h2>Hedge Funds Weigh In On Acumen Pharmaceuticals</h2>
<div class="lb-trans"><h2>對 Acumen Pharmaceuticals 的對沖基金看法</h2>
</div><p>Several large investors have recently made changes to their positions in the business. AQR Capital Management LLC bought a new stake in shares of Acumen Pharmaceuticals in the 1st quarter worth approximately $46,000. Y Intercept Hong Kong Ltd acquired a new position in Acumen Pharmaceuticals in the second quarter worth approximately $291,000. Marshall Wace LLP bought a new position in shares of Acumen Pharmaceuticals in the second quarter valued at $160,000. Qube Research &amp; Technologies Ltd increased its holdings in shares of Acumen Pharmaceuticals by 160.0% in the second quarter. Qube Research &amp; Technologies Ltd now owns 57,559 shares of the company's stock valued at $67,000 after buying an additional 35,424 shares in the last quarter. Finally, Jane Street Group LLC lifted its position in shares of Acumen Pharmaceuticals by 1,526.0% during the 2nd quarter. Jane Street Group LLC now owns 175,670 shares of the company's stock valued at $204,000 after acquiring an additional 164,866 shares during the last quarter. Institutional investors own 71.01% of the company's stock.</p>
<div class="lb-trans"><p>幾家大型投資者最近對該公司的持股進行了調整。AQR Capital Management LLC 在第一季度購買了 Acumen Pharmaceuticals 的新股份，價值約為 46,000 美元。Y Intercept Hong Kong Ltd 在第二季度收購了 Acumen Pharmaceuticals 的新股份，價值約為 291,000 美元。Marshall Wace LLP 在第二季度購買了 Acumen Pharmaceuticals 的新股份，價值為 160,000 美元。Qube Research &amp; Technologies Ltd 在第二季度將其在 Acumen Pharmaceuticals 的持股增加了 160.0%。Qube Research &amp; Technologies Ltd 現在擁有 57,559 股該公司的股票，價值 67,000 美元，此前在上個季度又購買了 35,424 股。最後，Jane Street Group LLC 在第二季度將其在 Acumen Pharmaceuticals 的持股增加了 1,526.0%。Jane Street Group LLC 現在擁有 175,670 股該公司的股票，價值 204,000 美元，此前在上個季度又收購了 164,866 股。機構投資者持有該公司 71.01% 的股票。</p>
</div><h2>About Acumen Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Acumen Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and related proteinopathies.</p>
<div class="lb-trans"><p>Acumen Pharmaceuticals, Inc.是一家臨牀階段的生物製藥公司，專注於發現和開發用於神經退行性疾病的口服小分子療法。該公司利用一種集成了化學蛋白質組學、高通量篩選和計算化學的專有藥物發現平台，旨在識別和優化選擇性調節病理性蛋白質聚集的化合物。其方法旨在解決阿爾茨海默病、帕金森病、肌萎縮側索硬化症及相關蛋白病等疾病的基礎生物學問題。</p>
</div><p>The company's pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.</p>
<div class="lb-trans"><p>該公司的產品管線包括多個處於不同臨牀前和早期臨牀開發階段的主要候選藥物。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Acumen Pharmaceuticals</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>Do not delete, read immediately</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>Best $19 you’ll spend this year.</li>
<li>First Time Since 2007: All Warnings Active</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Acumen Pharmaceuticals</li>
<li>Elon 將 SpaceX 上市！100 美元的首次公開募股機會！</li>
<li>請勿刪除，立即閲讀</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
<li>今年你花的最值得的 19 美元。</li>
<li>自 2007 年以來首次：所有警告均已激活</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUJPUw" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=ABOS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Acumen Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Acumen Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Acumen Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Acumen Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acumen Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前立即購買……而 Acumen Pharmaceuticals 並不在名單上。</p>
</div><p>While Acumen Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Acumen Pharmaceuticals 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

James Doherty 出售了 6,467 股 Acumen Pharmaceuticals（納斯達克代碼：ABOS）的股票